STOCK TITAN

[SCHEDULE 13G/A] Fulcrum Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports shared beneficial ownership of 4,589,000 shares of Fulcrum Therapeutics common stock, representing 8.50% of the class based on 53,979,306 shares outstanding. The shares are held directly by Adage Capital Partners, L.P., with Adage acting as investment manager and Messrs. Atchinson and Gross identified as managing members of the related entities.

The filing shows no sole voting or dispositive power; all voting and disposition power is reported as shared. The reporting persons certify the holdings are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Adage Capital Management, L.P., insieme a Robert Atchinson e Phillip Gross, dichiara la titolarità condivisa di 4,589,000 azioni ordinarie di Fulcrum Therapeutics, pari al 8.50% della categoria, sulla base di 53,979,306 azioni in circolazione. Le azioni sono detenute direttamente da Adage Capital Partners, L.P., con Adage in qualità di gestore degli investimenti e i sig. Atchinson e Gross indicati come membri gestori delle entità correlate.

La comunicazione segnala assenza di poteri di voto o di disposizione esclusivi; tutti i poteri di voto e di disposizione sono dichiarati come condivisi. Le persone che rendono la comunicazione certificano che le partecipazioni sono detenute nell'ordinaria attività d'impresa e non con l'obiettivo di modificare o influenzare il controllo dell'emittente.

Adage Capital Management, L.P., junto con Robert Atchinson y Phillip Gross, informa de la titularidad compartida de 4,589,000 acciones ordinarias de Fulcrum Therapeutics, que representan el 8.50% de la clase, sobre la base de 53,979,306 acciones en circulación. Las acciones están en posesión directa de Adage Capital Partners, L.P., con Adage actuando como gestor de inversiones y los señores Atchinson y Gross identificados como miembros gestores de las entidades relacionadas.

La presentación indica ausencia de poder de voto o de disposición exclusivo; todos los poderes de voto y de disposición se informan como compartidos. Las personas informantes certifican que las tenencias se mantienen en el curso ordinario del negocio y no con el propósito de cambiar o influir en el control del emisor.

Adage Capital Management, L.P.는 Robert Atchinson 및 Phillip Gross와 함께 Fulcrum Therapeutics 보통주 4,589,000주를 공동으로 보유하고 있음을 보고했습니다. 이는 전체 발행주식수 53,979,306주를 기준으로 해당 종류의 8.50%에 해당합니다. 해당 주식은 Adage Capital Partners, L.P.가 직접 보유하고 있으며 Adage는 투자관리자로서, Atchinson 씨와 Gross 씨는 관련 법인의 관리 멤버로 기재되어 있습니다.

보고서에는 단독 의결권 또는 처분권 없음으로 표시되어 있으며 모든 의결권과 처분권은 공동으로 보고되었습니다. 보고인은 보유가 통상적인 영업 범위 내에서 이루어진 것이며 발행인의 지배권을 변경하거나 영향력을 행사할 목적이 아님을 확인합니다.

Adage Capital Management, L.P., conjointement avec Robert Atchinson et Phillip Gross, déclare la propriété bénéficiaire partagée de 4,589,000 actions ordinaires de Fulcrum Therapeutics, représentant 8.50% de la catégorie sur la base de 53,979,306 actions en circulation. Les actions sont détenues directement par Adage Capital Partners, L.P., Adage agissant en tant que gestionnaire d'investissement et MM. Atchinson et Gross étant identifiés comme membres dirigeants des entités concernées.

Le dépôt indique aucun pouvoir de vote ni de disposition exclusif ; tous les pouvoirs de vote et de disposition sont déclarés partagés. Les personnes déclarante certifient que les participations sont détenues dans le cours normal des affaires et pas dans le but de modifier ou d'influencer le contrôle de l'émetteur.

Adage Capital Management, L.P. berichtet zusammen mit Robert Atchinson und Phillip Gross von gemeinsamem wirtschaftlichem Eigentum an 4,589,000 Aktien der Fulcrum Therapeutics-Stammaktien, was 8.50% der Klasse auf Grundlage von 53,979,306 ausstehenden Aktien entspricht. Die Aktien werden unmittelbar von Adage Capital Partners, L.P. gehalten, wobei Adage als Investmentmanager auftritt und die Herren Atchinson und Gross als geschäftsführende Mitglieder der betreffenden Einheiten genannt sind.

In der Meldung werden keine alleinigen Stimm- oder Verfügungsrechte angegeben; alle Stimm- und Verfügungsrechte werden als gemeinsam gemeldet. Die meldenden Personen versichern, dass die Bestände im gewöhnlichen Geschäftsbetrieb gehalten werden und nicht zum Zweck der Änderung oder Beeinflussung der Kontrolle des Emittenten dienen.

Positive
  • Material institutional stake disclosed: Adage beneficially owns 4,589,000 shares, representing 8.50% of Fulcrum's outstanding common stock.
  • Holdings held via established entity: Shares are held directly by Adage Capital Partners, L.P., indicating institutional involvement and reporting transparency.
Negative
  • No sole voting or dispositive power: The filing reports 0 shares of sole voting power and dispositive power; all power is shared, limiting unilateral influence.
  • Declared passive intent: The reporting persons certify the shares are held in the ordinary course and not to change or influence control, reducing the likelihood of near-term activist initiatives.

Insights

Adage reports a material passive stake of 8.5% in Fulcrum, a significant institutional holding but presented as non-activist.

The Schedule 13G discloses a 4,589,000 share position representing 8.50% of the outstanding common stock (based on 53,979,306 shares). That level exceeds the 5% disclosure threshold and is therefore materially relevant to shareholder composition. The filing indicates shared voting and dispositive power and a certification the stake is held in the ordinary course and not to influence control, which aligns with a passive institutional investor profile rather than an active or activist position.

Shared voting power and a 13G filing signal limited governance pressure now; material influence exists but no declared intent to pursue control.

From a governance perspective, a disclosed 8.50% holder can attract management attention and may qualify as a key institutional owner, yet the absence of sole voting or dispositive power and the explicit certification that the stake is not intended to change control point to a non-confrontational posture. Unless future filings or communications indicate activist intent, immediate governance risk or change is limited.

Adage Capital Management, L.P., insieme a Robert Atchinson e Phillip Gross, dichiara la titolarità condivisa di 4,589,000 azioni ordinarie di Fulcrum Therapeutics, pari al 8.50% della categoria, sulla base di 53,979,306 azioni in circolazione. Le azioni sono detenute direttamente da Adage Capital Partners, L.P., con Adage in qualità di gestore degli investimenti e i sig. Atchinson e Gross indicati come membri gestori delle entità correlate.

La comunicazione segnala assenza di poteri di voto o di disposizione esclusivi; tutti i poteri di voto e di disposizione sono dichiarati come condivisi. Le persone che rendono la comunicazione certificano che le partecipazioni sono detenute nell'ordinaria attività d'impresa e non con l'obiettivo di modificare o influenzare il controllo dell'emittente.

Adage Capital Management, L.P., junto con Robert Atchinson y Phillip Gross, informa de la titularidad compartida de 4,589,000 acciones ordinarias de Fulcrum Therapeutics, que representan el 8.50% de la clase, sobre la base de 53,979,306 acciones en circulación. Las acciones están en posesión directa de Adage Capital Partners, L.P., con Adage actuando como gestor de inversiones y los señores Atchinson y Gross identificados como miembros gestores de las entidades relacionadas.

La presentación indica ausencia de poder de voto o de disposición exclusivo; todos los poderes de voto y de disposición se informan como compartidos. Las personas informantes certifican que las tenencias se mantienen en el curso ordinario del negocio y no con el propósito de cambiar o influir en el control del emisor.

Adage Capital Management, L.P.는 Robert Atchinson 및 Phillip Gross와 함께 Fulcrum Therapeutics 보통주 4,589,000주를 공동으로 보유하고 있음을 보고했습니다. 이는 전체 발행주식수 53,979,306주를 기준으로 해당 종류의 8.50%에 해당합니다. 해당 주식은 Adage Capital Partners, L.P.가 직접 보유하고 있으며 Adage는 투자관리자로서, Atchinson 씨와 Gross 씨는 관련 법인의 관리 멤버로 기재되어 있습니다.

보고서에는 단독 의결권 또는 처분권 없음으로 표시되어 있으며 모든 의결권과 처분권은 공동으로 보고되었습니다. 보고인은 보유가 통상적인 영업 범위 내에서 이루어진 것이며 발행인의 지배권을 변경하거나 영향력을 행사할 목적이 아님을 확인합니다.

Adage Capital Management, L.P., conjointement avec Robert Atchinson et Phillip Gross, déclare la propriété bénéficiaire partagée de 4,589,000 actions ordinaires de Fulcrum Therapeutics, représentant 8.50% de la catégorie sur la base de 53,979,306 actions en circulation. Les actions sont détenues directement par Adage Capital Partners, L.P., Adage agissant en tant que gestionnaire d'investissement et MM. Atchinson et Gross étant identifiés comme membres dirigeants des entités concernées.

Le dépôt indique aucun pouvoir de vote ni de disposition exclusif ; tous les pouvoirs de vote et de disposition sont déclarés partagés. Les personnes déclarante certifient que les participations sont détenues dans le cours normal des affaires et pas dans le but de modifier ou d'influencer le contrôle de l'émetteur.

Adage Capital Management, L.P. berichtet zusammen mit Robert Atchinson und Phillip Gross von gemeinsamem wirtschaftlichem Eigentum an 4,589,000 Aktien der Fulcrum Therapeutics-Stammaktien, was 8.50% der Klasse auf Grundlage von 53,979,306 ausstehenden Aktien entspricht. Die Aktien werden unmittelbar von Adage Capital Partners, L.P. gehalten, wobei Adage als Investmentmanager auftritt und die Herren Atchinson und Gross als geschäftsführende Mitglieder der betreffenden Einheiten genannt sind.

In der Meldung werden keine alleinigen Stimm- oder Verfügungsrechte angegeben; alle Stimm- und Verfügungsrechte werden als gemeinsam gemeldet. Die meldenden Personen versichern, dass die Bestände im gewöhnlichen Geschäftsbetrieb gehalten werden und nicht zum Zweck der Änderung oder Beeinflussung der Kontrolle des Emittenten dienen.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Adage Capital Management, L.P.
Signature:/s/ Robert Atchinson
Name/Title:By: Adage Capital Partners LLC, its General Partner, By: Robert Atchinson, its Managing Member
Date:08/12/2025
Robert Atchinson
Signature:/s/ Robert Atchinson
Name/Title:Robert Atchinson, individually
Date:08/12/2025
Phillip Gross
Signature:/s/ Phillip Gross
Name/Title:Phillip Gross, individually
Date:08/12/2025

FAQ

How many Fulcrum (FULC) shares does Adage Capital disclose owning?

Adage Capital discloses beneficial ownership of 4,589,000 shares of Fulcrum common stock.

What percentage of Fulcrum does that stake represent?

The position represents 8.50% of the outstanding common stock based on 53,979,306 shares outstanding.

Does Adage have sole voting or dispositive power over these shares?

No. The filing reports 0 shares of sole voting or sole dispositive power; all voting and dispositive power is shared.

Are the shares held directly or on behalf of another entity?

The shares are reported as directly held by Adage Capital Partners, L.P., with Adage Capital Management serving as investment manager.

Does the filing indicate an intent to influence control of Fulcrum?

The reporting persons certify the holdings are held in the ordinary course of business and not for the purpose of changing or influencing control.

Who are the individual reporting persons named in the filing?

The filing names Robert Atchinson and Phillip Gross as reporting persons and managing members of the related Adage entities.
Fulcrum Therapeutics

NASDAQ:FULC

FULC Rankings

FULC Latest News

FULC Latest SEC Filings

FULC Stock Data

342.94M
53.10M
1.82%
95.92%
9.09%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE